you are here: HomeNewsBusiness

Buy Cipla; target of Rs 950: Sharekhan

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 950 in its research report dated January 29, 2021.

February 08, 2021 / 04:07 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Cipla

Q3FY2021 was a strong quarter with margins expanding sturdily on account of cost optimisation efforts. Results are ahead of estimates. Cipla’s One-India strategy has played out well and has yielded synergies across its business. Increased prescription generation backed by sustained traction in chronic and a likely revival in the acute therapy would drive growth of the India business. Healthy growth prospects across geographies, strong earnings visibility, and a healthy balance sheet augur well and will be key positives for Cipla.


We maintain our Buy recommendation on the stock of Cipla with an unchanged PT of Rs. 950.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Feb 8, 2021 04:07 pm

stay updated

Get Daily News on your Browser